Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 10

1.

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.

Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, Matthews T, Weinhold K, Bolognesi DP, Sposto R, et al.

JAMA. 1994 Aug 10;272(6):475-80.

PMID:
7913731
2.

The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.

O'Connell RJ, Kim JH, Excler JL.

Expert Rev Vaccines. 2014 Dec;13(12):1489-500. doi: 10.1586/14760584.2014.951335. Epub 2014 Aug 28. Review.

PMID:
25163695
3.

Induction of immunity to human immunodeficiency virus type-1 by vaccination.

McElrath MJ, Haynes BF.

Immunity. 2010 Oct 29;33(4):542-54. doi: 10.1016/j.immuni.2010.09.011. Review.

4.

HIV-1 vaccines: challenges and new perspectives.

Excler JL, Robb ML, Kim JH.

Hum Vaccin Immunother. 2014;10(6):1734-46. doi: 10.4161/hv.28462. Epub 2014 Mar 17. Review.

PMID:
24637946
5.

Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.

Lewis GK, DeVico AL, Gallo RC.

Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15614-21. doi: 10.1073/pnas.1413550111. Epub 2014 Oct 27. Review.

6.

Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination.

Polonis VR, Brown BK, Rosa Borges A, Zolla-Pazner S, Dimitrov DS, Zhang MY, Barnett SW, Ruprecht RM, Scarlatti G, Fenyƶ EM, Montefiori DC, McCutchan FE, Michael NL.

Virology. 2008 Jun 5;375(2):315-20. doi: 10.1016/j.virol.2008.02.007. Epub 2008 Mar 25. Review.

7.

Modulation of HIV-1 immunity by adjuvants.

Moody MA.

Curr Opin HIV AIDS. 2014 May;9(3):242-9. doi: 10.1097/COH.0000000000000052. Review.

8.

Receptor binding domain based HIV vaccines.

Liu H, Bi W, Wang Q, Lu L, Jiang S.

Biomed Res Int. 2015;2015:594109. doi: 10.1155/2015/594109. Epub 2015 Jan 15. Review.

9.

Human immunodeficiency virus: scientific challenges impeding candidate vaccines.

Idemyor V.

HIV Clin Trials. 2003 Nov-Dec;4(6):421-4. Review.

PMID:
14628286
10.

HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians.

VISR Working Group of Global HIV Vaccine Enterprise, Voronin Y, Zinszner H, Karg C, Brooks K, Coombs R, Hural J, Holt R, Fast P, Allen M.

Vaccine. 2015 Mar 3;33(10):1243-9. doi: 10.1016/j.vaccine.2014.10.040. Epub 2015 Jan 31. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk